论文部分内容阅读
目的了解紫杉特尔联合卡培他滨化疗方案治疗晚期胃癌的疗效和毒副作用。方法自2001年10月-2005年1月,有41例晚期胃癌病人入组,口服希罗达每日1650mg/(m2·d),连服1-14天,紫杉特尔75mg/m2静脉滴注,第1天应用,每3周为1周期,连用4周期;治疗结束2周后评价疗效、毒副反应。结果全组可评价病例39例,其中CR3例,PR18例,总有效率53.8%。主要毒副反应为骨髓抑制和手足综合征,绝大部分病人均能耐受。结论紫杉特尔联合卡培他滨化疗方案是目前治疗晚期胃癌较理想的方案。
Objective To investigate the curative effect and side effects of paclitaxel plus capecitabine in the treatment of advanced gastric cancer. Methods From October 2001 to January 2005, 41 patients with advanced gastric cancer were enrolled in this study. The daily dose of Xeloda was 1650 mg / (m2 · d), even for 1 to 14 days. The patients were also given the paclitaxel 75 mg / m2 intravenously Drip, the first day of application, every 3 weeks for 1 cycle, once every 4 cycles; 2 weeks after the end of treatment to evaluate the efficacy of toxic side effects. Results The whole group of 39 evaluable cases, including CR3 cases, PR18 cases, the total effective rate was 53.8%. The main side effects of myelosuppression and hand-foot syndrome, most patients can tolerate. Conclusion: Paclitaxel combined with capecitabine chemotherapy is the ideal treatment for advanced gastric cancer.